Insider Selling: Dianthus Therapeutics (NASDAQ:DNTH) EVP Sells $2,756,468.40 in Stock

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) EVP Simrat Randhawa sold 33,830 shares of the firm’s stock in a transaction on Thursday, March 12th. The shares were sold at an average price of $81.48, for a total transaction of $2,756,468.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Dianthus Therapeutics Stock Performance

Shares of DNTH opened at $77.86 on Monday. The stock has a market capitalization of $3.46 billion, a PE ratio of -18.99 and a beta of 1.56. The company’s fifty day moving average is $52.53 and its 200 day moving average is $42.82. Dianthus Therapeutics, Inc. has a fifty-two week low of $13.36 and a fifty-two week high of $88.02.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings data on Monday, March 9th. The company reported ($1.43) EPS for the quarter, missing the consensus estimate of ($0.97) by ($0.46). Dianthus Therapeutics had a negative net margin of 7,973.33% and a negative return on equity of 38.85%. The business had revenue of $0.57 million for the quarter, compared to the consensus estimate of $0.40 million. As a group, research analysts forecast that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on DNTH. Robert W. Baird increased their price target on shares of Dianthus Therapeutics from $67.00 to $132.00 and gave the company an “outperform” rating in a report on Tuesday, March 10th. Raymond James Financial raised Dianthus Therapeutics from an “outperform” rating to a “strong-buy” rating and boosted their price objective for the stock from $63.00 to $123.00 in a research note on Tuesday, March 10th. Jefferies Financial Group set a $98.00 price objective on Dianthus Therapeutics and gave the company a “buy” rating in a research report on Monday, March 9th. Stifel Nicolaus set a $120.00 price objective on Dianthus Therapeutics in a research note on Monday, March 9th. Finally, Truist Financial boosted their target price on Dianthus Therapeutics from $63.00 to $110.00 and gave the company a “buy” rating in a research report on Monday, March 9th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $115.33.

Hedge Funds Weigh In On Dianthus Therapeutics

A number of large investors have recently made changes to their positions in DNTH. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Dianthus Therapeutics by 4.2% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company’s stock valued at $280,000 after purchasing an additional 618 shares during the last quarter. Ensign Peak Advisors Inc bought a new stake in Dianthus Therapeutics in the second quarter worth about $2,504,000. American Century Companies Inc. boosted its position in shares of Dianthus Therapeutics by 13.2% during the second quarter. American Century Companies Inc. now owns 54,140 shares of the company’s stock valued at $1,009,000 after buying an additional 6,323 shares during the period. XTX Topco Ltd purchased a new position in shares of Dianthus Therapeutics during the second quarter valued at approximately $503,000. Finally, Sio Capital Management LLC grew its stake in shares of Dianthus Therapeutics by 101.8% during the second quarter. Sio Capital Management LLC now owns 236,070 shares of the company’s stock valued at $4,398,000 after buying an additional 119,073 shares during the last quarter. 47.53% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Dianthus Therapeutics

Here are the key news stories impacting Dianthus Therapeutics this week:

• Positive Sentiment: Company news: management announced an early Phase‑3 “go” decision and an upsized capital raise that sparked the recent rally; market reaction was enthusiastic because the program advancement de‑risked the story while the raise funds development and operations. Dianthus Therapeutics (DNTH) Is Up 30.8% After Upsized Raise And Early Phase 3 “Go” Decision
• Positive Sentiment: Financing closed: Dianthus completed an upsized underwritten offering that generated roughly $719M of gross proceeds (including full exercise of the underwriters’ option), strengthening the company’s cash runway for clinical work. This is a clear near‑term liquidity positive for investors. Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering…
• Positive Sentiment: Analyst upgrades: multiple firms (Raymond James, Wedbush, Robert W. Baird) issued bullish notes or raised their stance, which helped lift sentiment and trading activity. Upgrades add distribution and can attract momentum buyers. Dianthus Therapeutics (NASDAQ:DNTH) Raised to “Strong-Buy” at Raymond James Financial
• Positive Sentiment: Trading flow: the stock saw a large volume increase after analyst coverage/bullish headlines, indicating active repositioning by investors around the financing and clinical update. Higher volume can amplify price moves in either direction. Dianthus Therapeutics (NASDAQ:DNTH) Sees Large Volume Increase Following Analyst Upgrade
• Neutral Sentiment: Short-interest note: the most recent short‑interest data reported an anomalous zero‑share figure and essentially a 0.0 days‑to‑cover metric — likely a reporting quirk rather than a meaningful signal; treat with caution.
• Negative Sentiment: Analyst/model risk: HC Wainwright lowered near‑term and FY2026–FY2028 EPS forecasts substantially even while keeping a Buy rating and a high target; the cuts highlight expected cash burn and timing risk, which can pressure near‑term sentiment and invite profit‑taking.
• Negative Sentiment: Operational/financial backdrop: recent quarterly results included an EPS miss and very negative margins/returns, reminding investors that Dianthus remains a pre‑profit, high‑burn biotech—so upside is dependent on clinical progress and successful use of the new capital.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.